Single-Domain Antibody Transferrin Binding Serum Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for extending the serum half-life of short-lived proteins and peptides are inefficient, costly, and often complicated, with existing technologies like pegylation and fusion to albumin or Fc regions facing manufacturing and expression challenges.
Innovation Solution
Development of single-domain antibodies (sdAbs) specifically binding to transferrin, which are used to create fusion proteins that prolong the serum half-life of target proteins by leveraging transferrin's long serum half-life, with the sdAbs being purified and used to extend the pharmacokinetics of short half-life proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional methods like pegylation or fusion to albumin/Fc regions are used to extend serum half-life, then the serum half-life of short-lived proteins is improved, but the manufacturing complexity and cost increase significantly
Solution Approach 1:
The invention extracts the essential function of long half-life extension by isolating the binding domain (sdAb) from the complete antibody structure. Instead of using entire antibodies or complex fusion proteins like albumin-Fc, the patent employs minimal single-domain antibodies that retain only the critical transferrin-binding capability, thereby simplifying manufacturing while achieving the desired pharmacokinetic enhancement
Solution Approach 2:
The sdAb acts as an intermediary component that mediates between the short-lived therapeutic protein and the long-lived transferrin. This intermediate binding element transfers the long half-life property from transferrin to the therapeutic protein without requiring direct fusion to complex structures like albumin or full antibodies, thus reducing manufacturing complexity
2Duration of action of stationary object
If fusion proteins with albumin or Fc regions are created to prolong serum half-life, then the duration of action is improved, but expression levels and manufacturing efficiency deteriorate
Solution Approach 1:
The invention extracts only the essential binding domain (sdAb) from complete antibodies, creating a minimal functional unit that maintains high expression levels. This extracted domain is sufficient for transferrin binding and half-life extension, avoiding the manufacturing inefficiencies associated with expressing full-length antibodies or large fusion proteins like albumin-Fc
Solution Approach 2:
The sdAb represents a simplified, cost-effective alternative to expensive and complex fusion proteins. By using a small, single-domain antibody instead of large albumin-Fc fusion proteins or full antibodies, the invention reduces manufacturing costs and improves expression efficiency while achieving the same pharmacokinetic enhancement
3Duration of action of stationary object
If complex fusion proteins are used for half-life extension, then the serum half-life is improved, but the process safety and simplicity of use worsen
Solution Approach 1:
The invention extracts the essential half-life extension function into a minimal sdAb component, eliminating the need for complex fusion protein construction. This simplified approach allows for easier genetic engineering, simpler purification processes, and more straightforward regulatory approval compared to complex albumin-Fc or pegylated proteins
Solution Approach 2:
The sdAb serves as a simple intermediary that facilitates half-life extension through a single, well-defined binding interaction with transferrin. This intermediary approach avoids the complexity of multiple interaction interfaces found in fusion proteins, thereby improving process safety and simplifying manufacturing and characterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sdAbs effectively increase the serum half-life of target proteins by binding to transferrin, providing a more efficient, cost-effective, and stable therapeutic or diagnostic tool, overcoming previous challenges in protein half-life extension.
Implementation Method 1
single-domain antibodies (sdAbs) that specifically recognize transferrin... an isolated antibody or antigen-binding fragment thereof that specifically binds a transferrin
Implementation Method 2
a polypeptide comprising at least one immunoglobulin single domain antibody (sdAb) that specifically binds human and cynomolgus monkey serum transferrin protein and protein A resin
Data Source
AI summary
Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.